U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
HOPKINTON, Mass., Oct. 13, 2016 -- Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals will present at the Dawson James Securities 2016 Stock Growth Conference on Thursday, October 20th at 10:45 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida. For more information on the conference or for investors to register, please go to DJS Conference. To view the live audio webcast of the presentation please go to http://ir.springbankpharm.com or http://wsw.com/webcast/dawson2/sbph.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. For more information please visit: www.springbankpharm.com.
About Dawson James Securities
Dawson James Securities, Inc., a member of FINRA/SIPC, is a full service investment bank headquartered in Boca Raton, FL. http://www.dawsonjames.com.
Contact: Jon Freve Chief Financial Officer (508) 500-4956 [email protected]
